Status:
ENROLLING_BY_INVITATION
Optimal Duration of Bismuth Quadruple Therapy for Helicobacter Pylori Eradication in Females As Compared with Males
Lead Sponsor:
National Cheng-Kung University Hospital
Conditions:
Helicobacter Pylori Infection
Sex
Eligibility:
All Genders
18-100 years
Phase:
PHASE4
Brief Summary
Helicobacter pylori eradication can reduce the risk of gastric cancer and decrease the recurrence of ulcers. However, in recent years, the increasing antibiotic resistance of Helicobacter pylori has r...
Detailed Description
The recently published real-world study on Helicobacter pylori treatment, revealing that female (odds ratio 2.41 \[95% confidence interval (CI) 1.16-5.03\], P = 0.02) and age-Charlson Comorbidity Inde...
Eligibility Criteria
Inclusion
- Patients who are \> 18 years
- H. pylori infection confirmed by histology of a gastric biopsy, a positive rapid urease test, or a positive 13C-urea breath test.
Exclusion
- History of H. pylori eradication
- Previous allergic reactions to any drugs in the bismuth quadruple therapy
- Severe comorbidities
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
July 9 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2032
Estimated Enrollment :
661 Patients enrolled
Trial Details
Trial ID
NCT06509139
Start Date
July 9 2024
End Date
July 31 2032
Last Update
November 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Helicobacter pylori study group, National Cheng Kung University Hospital
Tainan, Taiwan, 70403